Skip to main content
. Author manuscript; available in PMC: 2014 Nov 1.
Published in final edited form as: Anticancer Drugs. 2013 Nov;24(10):10.1097/CAD.0000000000000017. doi: 10.1097/CAD.0000000000000017

Figure 5.

Figure 5

Interactions of compound 4 with caspases 3 and 9. (A) Effects of compound 4 on caspases 3 and 9 activities in SW-480 cells. After treatment with 1–15 μM of compound 4 for 24 h, cell lysates were prepared and enzymatic activities of caspases 3 and 9 were measured by colorimetric assay. Results are normalized to each control and expressed as average ± SD of triplicate experiments (*P<0.05, **P<0.01 vs. control). (B) Western blot analysis of caspases 3 and 9. SW-480 cells were treated with 1–15 μM of compound 4 for 24 h. (C) Three-dimensional docking model of compound 4 at the binding site of human caspase 9 protein. Compound 4 docked with caspase 9 through hydrogen bond interactions with residues Asp-340 and Ser-339. Surface views are shown in the left panel and stick-ribbon models are shown in the right.